The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review

por van Acht, Maartje R, van den Reek, Juul M P A, de Jong, Elke M G J, Seyger, Marieke M B
Publicado 2022

Global Risk of Bacterial Skin Infections and Herpesviridae Infections with Ustekinumab, Secukinumab, and Tumour Necrosis Factor-alpha Inhibitors: Spontaneous Reports of Adverse Dru...

por DAVIDSON, Linda, VAN DEN REEK, Juul M. P. A., VAN HUNSEL, Florence, DE JONG, Elke M. G. J., KULLBERG, Bart Jan
Publicado 2022

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab

por van der Schoot, Lara S., Atalay, Selma, Otero, Marisol E., Kievit, Wietske, van den Reek, Juul M.P.A., de Jong, Elke M.G.J.
Publicado 2022

The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy...

por van Muijen, Marloes E, van Hal, Tamara W, Groenewoud, Hans M M, van den Reek, Juul M P A, de Jong, Elke M G J
Publicado 2020

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

por Dekkers, Coco, Alizadeh Aghdam, Mehran, de Graaf, Marlies, Knulst, André C., Meijer, Yolanda, van den Reek, Juul M. P.A., Stadermann, Marike B., Röckmann, Heike
Publicado 2021

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-i...

por van der Schoot, Lara S., van den Reek, Juul M. P. A., Grine, Lynda, Schots, Lisa, Kievit, Wietske, Lambert, Jo L. W., de Jong, Elke M. G. J.
Publicado 2021

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice

por ATALAY, Selma, VAN DER SCHOOT, Lara S., VANDERMAESEN, Laura, VAN VUGT, Lieke J., EILANDER, Mascha, VAN DEN REEK, Juul M. P. A., DE JONG, Elke M. G. J.
Publicado 2021

Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks

por TER HAAR, Elke L. M., VAN DEN REEK, Juul M. P. A., GAARN DU JARDIN, Kristian, BARBERO-CASTILLO, Almudena, DE JONG, Elke M. G. J., LUBEEK, Satish F. K.
Publicado 2023

Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort

por VAN HAL, Tamara W., MULDER, Michelle L. M., WENINK, Mark H., PASCH, Marcel C., VAN DEN HOOGEN, Frank H. J., VAN DEN REEK, Juul M. P. A., DE JONG, Elke M. G. J.
Publicado 2022

Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial

por Atalay, Selma, van den Reek, Juul M. P. A., van Vugt, Lieke J., Otero, Marisol E., van de Kerkhof, Peter C. M., den Broeder, Alfons A., Kievit, Wietske, de Jong, Elke M. G. J.
Publicado 2017

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis

por VAN MUIJEN, Marloes E., THOMAS, Sarah E., VELLINGA, Douwe, BOUWMAN, Silke, VAN DOORN, Martijn B. A., POLITIEK, Klaziena, OTERO, Marisol E., VAN DEN REEK, Juul M. P. A., DE JONG, Elke M. G. J.
Publicado 2022

Development of a New Referral Tool to Identify Psoriasis Patients with Concomitant Psoriatic Arthritis: Results of the Prospective DAPPER Cohort

por VAN HAL, Tamara W., MULDER, Michelle L. M., WENINK, Mark H., VAN DEN HOOGEN, Frank H. J., MAURITS, Jake S. F., PASCH, Marcel C., VAN DEN REEK, Juul M. P. A., DE JONG, Elke M. G. J.
Publicado 2023

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review

por Mulder, Michelle L. M., van Hal, Tamara W., Wenink, Mark H., Koenen, Hans J. P. M., van den Hoogen, Frank H. J., de Jong, Elke M. G. J., van den Reek, Juul M. P. A., Vriezekolk, Johanna E.
Publicado 2021

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

por Davidson, Linda, van den Reek, Juul M.P.A., Bruno, Mariolina, van Hunsel, Florence, Herings, Ron M.C., Matzaraki, Vasiliki, Boahen, Collins K., Kumar, Vinod, Groenewoud, Hans M.M., van de Veerdonk, Frank L., Netea, Mihai G., de Jong, Elke M.G.J., Kullberg, Bart Jan
Publicado 2021

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analys...

por ATALAY, Selma, VAN DEN REEK, Juul M. P. A., OTERO, Marisol E., NJOO, Marcellus D., MOMMERS, Johannes M., OSSENKOPPELE, Paul M., KOETSIER, Marjolein I., BERENDS, Maartje A., VAN DE KERKHOF, Peter C. M., GROENEWOUD, Hans M. M., DEN BROEDER, Alfons A., DE JONG, Elke M. G. J., KIEVIT, Wietske
Publicado 2020

Blood-Based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients

por Mulder, Michelle L. M., He, Xuehui, van den Reek, Juul M. P. A., Urbano, Paulo C. M., Kaffa, Charlotte, Wang, Xinhui, van Cranenbroek, Bram, van Rijssen, Esther, van den Hoogen, Frank H. J., Joosten, Irma, Alkema, Wynand, de Jong, Elke M. G. J., Smeets, Ruben L., Wenink, Mark H., Koenen, Hans J. P. M.
Publicado 2021

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort

por VAN MUIJEN, Marloes. E., THOMAS, Sarah E., GROENEWOUD, Hans M. M., OTERO, Marisol E., OSSENKOPPELE, Paul M., NJOO, Marcellus D., DODEMONT, Sharon R. P., KOP, Else N., BERENDS, Maartje A. M., KOETSIER, Marjolein I. A., MOMMERS, Johannes M., KÖRVER, John E. M., TUPKER, Ron A., DE BRUIN-WELLER, Marjolein S., WEPPNER-PARREN, Lizelotte J. M. T., PETERS, Bas, KLEINPENNING, Marloes M., KUIJPERS, Astrid L. A., ARNOLD, W. Peter, VAN LÜMIG, Paula P. M., VAN DEN REEK, Juul M. P. A., DE JONG, Elke M. G. J.
Publicado 2022